alogliptin benzoate; pioglitazone hydrochloride · Takeda Pharms Usa · NDA 022426
Oseni
Earliest generic entry, as listed · earliest of 4 marketed strengths
4 Jun 2029
Blocked by patent: US 8637079.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8637079 | product | 4 Jun 2029 |
| US 7807689 | substance, product, use U-1337 | 27 Jun 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022426 · 001 · RLD | tablet, oral | EQ 25MG BASE;EQ 15MG BASE | 4 Jun 2029 |
| 022426 · 002 · RLD | tablet, oral | EQ 25MG BASE;EQ 30MG BASE | 4 Jun 2029 |
| 022426 · 003 · RLD | tablet, oral | EQ 25MG BASE;EQ 45MG BASE | 4 Jun 2029 |
| 022426 · 004 · RLD · discontinued | tablet, oral | EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 4 Jun 2029 |
| 022426 · 005 · RLD | tablet, oral | EQ 12.5MG BASE;EQ 30MG BASE | 4 Jun 2029 |
| 022426 · 006 · RLD · discontinued | tablet, oral | EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 4 Jun 2029 |